Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

276 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rate and determinants of 10-year persistence with antihypertensive drugs.
Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Van Wijk BL, et al. J Hypertens. 2005 Nov;23(11):2101-7. doi: 10.1097/01.hjh.0000187261.40190.2e. J Hypertens. 2005. PMID: 16208154
Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?
Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A. Mantel-Teeuwisse AK, et al. Br J Clin Pharmacol. 2002 Apr;53(4):379-85. doi: 10.1046/j.1365-2125.2002.01562.x. Br J Clin Pharmacol. 2002. PMID: 11966669 Free PMC article.
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM. Klungel OH, et al. Ann Pharmacother. 2002 May;36(5):751-7. doi: 10.1345/aph.1A308. Ann Pharmacother. 2002. PMID: 11978147
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.
Maitland-van der Zee AH, Klungel OH, Stricker BH, Monique Verschuren WM, Kastelein JJ, Leufkens HG, de Boer A. Maitland-van der Zee AH, et al. Atherosclerosis. 2002 Aug;163(2):213-22. doi: 10.1016/s0021-9150(01)00725-0. Atherosclerosis. 2002. PMID: 12052467 Review.
Quality of hypertension treatment and risk of stroke in the general population.
Klungel OH. Klungel OH. J Hypertens. 2002 Oct;20(10):1949-50. doi: 10.1097/00004872-200210000-00012. J Hypertens. 2002. PMID: 12359971 No abstract available.
The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype.
Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, Breteler MM, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Pharmacogenetics. 2002 Nov;12(8):647-53. doi: 10.1097/00008571-200211000-00009. Pharmacogenetics. 2002. PMID: 12439225
Myopathy due to statin/fibrate use in the Netherlands.
Mantel-Teeuwisse AK, Klungel OH, Herings RM, van Puijenbroek EP, Porsius AJ, de Boer A. Mantel-Teeuwisse AK, et al. Ann Pharmacother. 2002 Dec;36(12):1957-60. doi: 10.1345/aph.1C097. Ann Pharmacother. 2002. PMID: 12452761
Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?
Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HG, Grobbee DE. Spoelstra JA, et al. Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):121-7. doi: 10.1002/pds.760. Pharmacoepidemiol Drug Saf. 2003. PMID: 12642975
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.
Maitland-van der Zee AH, Stricker BH, Klungel OH, Mantel-Teeuwisse AK, Kastelein JJ, Hofman A, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Pharmacogenetics. 2003 Apr;13(4):219-23. doi: 10.1097/00008571-200304000-00006. Pharmacogenetics. 2003. PMID: 12668918
Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study.
Maitland-van der Zee AH, Klungel OH, Stricker BH, van der Kuip DA, Witteman JC, Hofman A, Leufkens HG, de Boer A. Maitland-van der Zee AH, et al. Pharm World Sci. 2003 Apr;25(2):70-2. doi: 10.1023/a:1023292830670. Pharm World Sci. 2003. PMID: 12774567
276 results
Jump to page
Feedback